H.R. 9421House119th Congress (2025-2027)In Committee

Ban Abortion by Mail Act

Introduced June 24, 2026

AI-Generated Summary

Updated July 15, 2026 at 2:20 PM UTC

The Ban Abortion by Mail Act would stop doctors who are certified under the FDA’s REMS program for mifepristone from prescribing the drug unless they see the patient in person and are licensed in the patient’s state. Providers who break these rules would lose their REMS certification for at least two years, and the government would report such losses to Congress each year. The bill mainly affects REMS‑certified providers and patients seeking medication abortions.

Key Provisions

  • A REMS‑certified provider who prescribes, dispenses, or administers mifepristone (or any abortion drug) without first seeing the patient in person loses their REMS certification for at least two years.
  • A REMS‑certified provider who prescribes mifepristone to a patient in a state where the provider does not hold a medical license also loses that certification for at least two years.
  • The Secretary of Health and Human Services must report each year to Congress the names of providers who have lost REMS certification because of these violations or unsafe prescribing.
  • The bill defines “abortion drug,” “REMS‑certified status,” “REMS‑certified provider,” and clarifies that the Secretary refers to the HHS Secretary acting through the FDA Commissioner.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
HouseIntro Referral Latest Action

Referred to the House Committee on Energy and Commerce.

June 24, 2026

View full timeline
HouseIntro Referral

Introduced in House

June 24, 2026

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

June 24, 2026

Floor Debate

1 member

What members said about H.R. 9421 on the floor

1 Republican
Monica De La Cruz
Rep. Monica De La CruzR-TX-15 · Jul 9, 2026

Under clause 7 of rule XII, sponsors were added to public bills and resolutions, as follows: H.R. 7: Mr. Van Epps. H.R. 138: Ms. Norton, Ms. Hoyle of Oregon, and Mr. Calvert. H.R. 491: Ms. Wilson of…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued June 24, 2026

I

119th CONGRESS

2d Session

H. R. 9421

IN THE HOUSE OF REPRESENTATIVES

June 24, 2026

Mrs. Biggs of South Carolina (for herself, Mr. Fry, and Mr. Norman) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.

1.

Short title

This Act may be cited as the Ban Abortion by Mail Act.

2.

Findings

The Congress finds the following:

(1)

Mifepristone can only be prescribed by a health care provider certified under the Mifepristone Risk Evaluation and Mitigation Strategies (REMS) Program.

(2)

Medical experts have advised that patients should be closely observed for signs and symptoms of adverse effects.

(3)

The purpose of Risk Evaluation and Mitigation Strategies (REMS) is to ensure the benefits of a drug outweigh its risks, especially for drugs with serious safety concerns.

3.

Health care provider REMS-certified status

(a)

In-Person visit required

Any REMS-certified provider that knowingly prescribes, dispenses, or administers mifepristone or any other abortion drug without an in-person visit with the patient for whom such drug is prescribed shall lose REMS-certified status, with respect to such drug, for a period of not less than 2 years.

(b)

License in patient’s State required

Any REMS-certified provider that knowingly prescribes, dispenses, or administers mifepristone or any other abortion drug to a patient residing in a State where the provider does not have a medical license shall lose REMS-certified status, with respect to such drug, for a period of not less than 2 years.

(c)

Reporting

The Secretary shall, on an annual basis, submit to Congress a report listing each REMS-certified provider who has lost REMS-certified status due to—

(1)

a violation of this section; or

(2)

improper or unsafe prescribing of mifepristone or any other abortion drug.

(d)

Definitions

In this section:

(1)

Abortion drug

The term abortion drug means any drug, substance, or combination of drugs or substances that is intended for use or that is in fact used (irrespective of how the product is labeled) to intentionally kill the unborn child of a woman known to be pregnant, or to intentionally terminate the pregnancy of a woman known to be pregnant, with an intention other than—

(A)

to produce a live birth;

(B)

to remove a dead unborn child; or

(C)

to treat an ectopic pregnancy.

(2)

REMS-certified status

The term REMS-certified status means, with respect to mifepristone or any other abortion drug, the certification of a REMS-certified provider by the Secretary to dispense such drug pursuant to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1).

(3)

REMS-certified provider

The term REMS-certified provider means a health care professional who has successfully completed the FDA’s Risk Evaluation and Mitigation Strategy (REMS) certification program for prescribing mifepristone.

(4)

Secretary

The term Secretary means the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs.